Filing summary
Entity mismatch: The supplied filing is Catalyst Biosciences, Inc.’s Form 10-Q for the quarter ended September 30, 2018—not a filing identified as Gyre Therapeutics, Inc. Confirm the issuer before relying on this summary.
Business context and reporting period
Catalyst was a clinical-stage biotechnology company focused on engineered clotting-factor therapies, particularly for hemophilia. The filing reports the three and nine months ended September 30, 2018, with comparisons to 2017. It had no approved products or commercial product sales.
Financial performance and liquidity
| Metric | Q3 2018 | Q3 2017 | Nine months 2018 | Nine months 2017 |
|---|---|---|---|---|
| Contract revenue | $0 | $0.318 million | $0.006 million | $0.700 million |
| Research and development expense | $5.575 million | $3.805 million | $13.235 million | $9.286 million |
| General and administrative expense | $2.770 million | $2.391 million | $8.909 million | $7.407 million |
| Net loss | $7.694 million | $5.793 million | $19.218 million | $15.808 million |
| Basic and diluted loss per share | $0.64 | $1.34 | $1.75 | $6.49 |
For the nine-month period, operating expenses rose 33% and net loss rose 22% year over year. Contract revenue declined as the ISU Abxis collaboration’s revenue recognition ended in February 2018. The company reported no product-sales gross margin; the filing does not provide a meaningful gross-margin measure.
- At September 30, cash and cash equivalents were $36.0 million, short-term investments $93.2 million, and restricted cash $0.05 million. Cash, cash equivalents, and short-term investments totaled approximately $129.2 million.
- Nine-month operating cash use was $19.5 million; investing cash use was $75.5 million, mainly reflecting purchases of short-term investments; financing provided $111.3 million. Cash, cash equivalents, and restricted cash increased $16.2 million.
- Total liabilities were $3.5 million. The $5.1 million redeemable convertible notes were repaid at maturity in February 2018; none remained outstanding at quarter-end. Lease obligations totaled $2.7 million, and AGC manufacturing obligations were reported at $3.9 million.
- Stockholders’ equity was $130.0 million and accumulated deficit was $192.5 million at quarter-end. The company had 11.94 million common shares outstanding.
The company stated that existing cash, cash equivalents, and short-term investments were expected to fund cash requirements for at least 12 months from the filing date. This depends on assumptions and is not a guarantee.
Material changes and unusual items
- In February 2018, Catalyst raised approximately $106.8 million net through a public offering of 3.38 million shares at $34 per share. Warrant exercises provided a further $9.5 million during the first nine months.
- Operating expenses increased with higher personnel, preclinical research, and manufacturing costs for MarzAA and DalcA. Research and development expense increased 43% for the nine-month period.
- Nine-month interest and other income was $2.9 million, including a $1.5 million milestone payment tied to neuronal nicotinic receptor assets previously sold and increased investment income. These items contributed to results but are not recurring product revenue.
- Adoption of ASC 606 produced a $0.2 million adjustment to opening accumulated deficit. The filing says the change affected timing of recognition for collaboration revenue.
Outlook, management commentary, and key risks
- MarzAA: The Phase 2/3 subcutaneous trial was enrolling up to 12 participants; five had been enrolled by September 30. Management anticipated completing Phase 2 enrollment by year-end 2018. Two participants completed treatment without bleeding over the reported dosing periods; another had a bleed and was dose-escalated. One participant with untreated severe hypertension died in a serious adverse event that the company said was not related to study drug. No anti-drug antibodies, injection-site reactions, or thrombotic events had been detected to date.
- DalcA: In cohort 6, two patients had promising Factor IX activity increases but developed neutralizing antibodies to DalcA. The company was investigating possible causes and stated it would decide whether to proceed with a Phase 2b study after completing analyses; no commitment to proceed was made. Prior cohorts had not shown these antibodies.
- Management expected research and development spending to rise in coming quarters, including as Catalyst assumed future DalcA development costs previously borne by ISU Abxis. The Factor Xa program was delayed to focus resources on Factor VIIa and Factor IX; the company continued to explore licensing opportunities for its dry AMD anti-complement program.
- Key risks include clinical failure or delays, antibody or other safety findings, manufacturing and third-party dependence, competition, and the need for additional financing. Catalyst warned that financing may not be available on acceptable terms and that it could reduce or delay programs if funds were insufficient. It had up to $17.5 million of contingent Pfizer milestone payments and a potential single-digit royalty on covered product sales if commercialized.
- The company reported no material legal proceedings and no off-balance-sheet arrangements. Management concluded disclosure controls were effective as of September 30, 2018.
Most important facts for investors to verify
- Confirm issuer identity: this is Catalyst Biosciences’ filing, despite the request metadata naming Gyre Therapeutics.
- Check subsequent MarzAA enrollment, clinical results, and safety updates, including the reported death and its stated unrelatedness to study drug.
- Track the investigation into DalcA neutralizing antibodies and whether the company proceeded with further clinical development.
- Assess actual cash burn and financing needs against management’s stated minimum 12-month runway, planned spending increases, and contractual and contingent obligations.
- Verify share-count changes and potential dilution from future offerings, outstanding options, and other securities.